Plan for ordinary profit of ¥2.03 billion and an ordinary profit margin of 13.2% in the next fiscal year
First written in FY2018. 2 of 4 entries say "Raised", first in FY2019-Q2. Latest entry: FY2021.
The whole theme swung hardest in 2023: 9 of 47 companies on the "Worse" side.
0 other companies' latest entry also says "Raised".
- FY2021RaisedAnnual report
「Against an ordinary profit margin of 15.8% in the current fiscal year, we expect the margin to rise next fiscal year as sales efficiency improves. However, taking into account the impact of the change in accounting standards, upfront investment in web marketing, replacement of the core system, and higher costs from new product sales, we plan an ordinary profit margin of 15.9%.」
The plan for next fiscal year’s ordinary profit margin was raised from the previous 12.9% to 15.9%. While an improvement in sales efficiency is expected, higher costs related to web marketing, the core system, and new products are also incorporated. - FY2020SoftenedAnnual report
「In light of the impact of the novel coronavirus, we plan for this indicator to be 12.9% next fiscal year.」
The outlook was changed from the previous plan of ordinary profit of ¥2,030 million and an ordinary profit margin of 13.2% next fiscal year to an outlook for an ordinary profit margin of 12.9%, without disclosing an ordinary profit figure for next fiscal year. - FY2019-Q2RaisedAnnual report
「Following strong performance in the first half, we revised our full-year forecasts upward to sales of ¥15,430 million, up 10.0% from the previous fiscal year, operating profit of ¥2,440 million, up 51.9%, ordinary profit of ¥2,345 million, up 39.4%, and profit attributable to owners of the parent of ¥1,460 million, up 23.5%. Strong performance in the direct-sales division and an improvement in the cost ratio from higher production of the new product launched last September resulted in gross profit exceeding the initial forecast.」
The full-year forecasts were revised upward to ordinary profit of ¥2,345 million and profit attributable to owners of the parent of ¥1,460 million. The factors cited were strong performance in the direct-sales division and an improved cost ratio resulting from increased production of the new product. - FY2018First statedAnnual report
「As the hospital operations business will remain in an investment period for future growth next fiscal year, we expect an equity-method investment loss of ¥180 million. However, through improvements in sales efficiency and the cost ratio, we plan ordinary profit of ¥2,030 million, up 10.2% from the current fiscal year, and an ordinary profit margin of 13.2%, up 1.2 percentage points.」
For next fiscal year, the company plans ordinary profit of ¥2,030 million and an ordinary profit margin of 13.2%, while expecting investment losses in the hospital operations business and improvements in sales efficiency and the cost ratio.